Drug Trial Radar · NCT06772623
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
252
Planned (sponsor's estimate)
Start
Mar 6, 2025
Primary completion
Nov 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Jan 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) immune checkpoint inhibitor to adult participants to treat NSCLC. Telisotuzumab Adizutecan (ABBV-400) and budigalimab are investigational drugs being developed for the treatment of NSCLC. This study will be divided into two stages, with the first stage treating participants with several doses of telisotuzumab adizutecan in combination with budigalimab within the dose escalation regimen until the dose reached is tolerable and expected to be efficacious. In Stage 2 there will be 3 treatment groups. Two groups will receive pembrolizumab with different optimized doses of telisotuzumab adizutecan (to allow for the best dose to be studied in the future). One group will receive the standard of care (SOC) - pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. Approximately 252 adult participants with NSCLC will be enrolled in the study in 132 sites worldwide. In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of Telisotuzumab Adizutecan in combination with budigalimab until the dose of Telisotuzumab Adizutecan reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive IV optimized doses of Telisotuzumab Adizutecan in combination with IV pembrolizumab, or IV SOC - pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. The study will run for a duration of approximately 33 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Conditions
- Non Small Cell Lung Carcinoma
- c-MET
Interventions
Telisotuzumab AdizutecanDrug
Intravenous (IV) Infusion
BudigalimabDrug
IV Infusion
PembrolizumabDrug
IV Injection
PembrolizumabDrug
IV Infusion
CarboplatinDrug
IV Infusion
PemetrexedDrug
IV Infusion
CisplatinDrug
IV Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Dose-Limiting Toxicities (DLT)s of Telisotuzumab AdizutecanTime frame: Up to Approximately 84 Days
- Part 2: Objective Response (OR) as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to Approximately 33 Months
- Number of Participants with Adverse Events (AE)sTime frame: Up to Approximately 33 Months
Locations
131 sites in 17 countries. Site status is shown where the registry gives one.
Mayo Clinic Hospital - Phoenix /ID# 272971
Phoenix, Arizona · Active not recruiting
Providence - St. Jude Medical Center /ID# 271414
Fullerton, California · Recruiting
FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 274450
Oxnard, California · Recruiting
UCLA - Santa Monica /ID# 271690
Santa Monica, California · Recruiting
University Of Colorado - Anschutz Medical Campus /ID# 269069
Aurora, Colorado · Recruiting
Rocky Mountain Cancer Centers - Lone Tree /ID# 272603
Lone Tree, Colorado · Recruiting
Mayo Clinic Hospital Jacksonville /ID# 275073
Jacksonville, Florida · Recruiting
Mid Florida Hematology And Oncology Center /ID# 273777
Orange City, Florida · Recruiting
Hope And Healing Cancer Services /ID# 276223
Hinsdale, Illinois · Recruiting
Parkview Comprehensive Cancer Center /ID# 271879
Fort Wayne, Indiana · Recruiting
Community Health Network /ID# 273437
Indianapolis, Indiana · Completed
Kansas City Cancer Center /ID# 273679
Overland Park, Kansas · Recruiting
Dana-Farber Cancer Institute /ID# 278417
Boston, Massachusetts · Recruiting
Henry Ford Hospital - Detroit /ID# 271642
Detroit, Michigan · Recruiting
St. Luke'S /ID# 273344
Duluth, Minnesota · Recruiting
Mayo Clinic-Rochester /ID# 274512
Rochester, Minnesota · Recruiting
Astera Cancer Care /ID# 271915
East Brunswick, New Jersey · Recruiting
New York Cancer And Blood Specialists - Shirley /ID# 272547
Shirley, New York · Recruiting
University Hospitals Cleveland Medical Center /ID# 271726
Cleveland, Ohio · Completed
The Mark H Zangmeister Center /ID# 272502
Columbus, Ohio · Recruiting
Spoknwrd Clinical Trials /ID# 273776
Easton, Pennsylvania · Recruiting
Millennium Physicians /ID# 271717
Houston, Texas · Completed
Joe Arrington Cancer Research /ID# 272776
Lubbock, Texas · Recruiting
Huntsman Cancer Institute /ID# 271686
Salt Lake City, Utah · Recruiting
Virgnia Cancer Specialists /ID# 269633
Leesburg, Virginia · Recruiting
Vista Oncology - East Olympia /ID# 275438
Olympia, Washington · Recruiting
Northwest Medical Specialties Tacoma /ID# 270469
Tacoma, Washington · Recruiting
Centro Oncologico Korben /ID# 281460
Buenos Aires, Argentina · Recruiting
Fundacion Respirar /ID# 281039
Buenos Aires, Argentina · Recruiting
Clinca Colon /ID# 281465
Mar del Plata, Buenos Aires, Argentina · Recruiting
Instituto Alexander Fleming /ID# 282704
Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., Argentina · Recruiting
Blacktown Hospital /ID# 281588
Blacktown, New South Wales, Australia · Recruiting
Townsville University Hospital /ID# 281498
Townsville, Queensland, Australia · Recruiting
Lyell Mcewin Hospital /ID# 281860
Elizabeth Vale, South Australia, Australia · Recruiting
Peninsula University Hospital /ID# 281824
Frankston, Victoria, Australia · Recruiting
Groupe Sante CHC - Clinique du MontLegia /ID# 271760
Liège, Belgium · Recruiting
Jessa Ziekenhuis - Campus Virga Jesse /ID# 268573
Hasselt, Limburg, Belgium · Recruiting
Vitaz /Id# 280187
Sint-Niklaas, Oost-Vlaanderen, Belgium · Recruiting
AZ-Delta. /ID# 272433
Roeselare, West-Vlaanderen, Belgium · Recruiting
Pontificia Universidad Catolica De Chile /ID# 281594
Santiago, Region Metropolitana Santiago, Chile · Recruiting
Showing 40 of 131 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.